Fierce Biotech June 7, 2024
Ipsen is hot on Marengo Therapeutics’ ability to treat “cold” tumors. The French drugmaker has agreed to pay Marengo up to $1.2 billion to access a T-cell engager platform for targeting immunologically cold tumors that are typically resistant to immunotherapies.
Marengo began working with Ipsen in 2022. At that time, Ipsen paid the biotech $45 million for rights to two drug candidates from its STAR platform. STAR enhances antibodies with T cell costimulatory signals to try to boost the immune response in “hot” tumors that are likely to respond to immunotherapy. The biotech’s other platform, TriSTAR, is designed for tumors that are unlikely to respond to immunotherapy.
Cold tumors lack the attributes to support robust anti-cancer immune responses, for example...
Today's Sponsors
Today's Sponsor